Literature DB >> 6243465

Studies of serum immunoglobulin binding to synovial fibroblast cell cultures from patients with rheumatoid arthritis.

W B Gruhn, F C McDuffie.   

Abstract

Using a sensitive 125I-protein A (PrA) binding assay to detect cell surface IgG, we have studied seven different synovial fibroblast cell cultures from patients with rheumatoid arthritis (RA). When these cultures were incubated in the presence of serum from 18 autologous and allogeneic RA patients (all seropositive), we were unable to detect significant IgG binding. Since IgM rheumatoid factor (RF) can block PrA binding, sera were absorbed with aggregated IgG to remove RF without affecting the results. Similar studies on three cell lines with seven rheumatoid sera were performed by antibody-dependent cell-mediated cytotoxicity. No significant cytotoxicity was observed. Since antibodies to collagen are present in rheumatoid sera, several cultures were incubated with ascorbic acid (12.5 microgram/ml) to optimize synthesis of cell surface collagen. These culture conditions did not affect serum immunoglobulin binding by the 125I-PrA assay. Thus, we can find no evidence for a direct humoral immune mediation of synovial proliferation in rheumatoid arthritis. These data do not support the hypothesis that the inflammatory process within the synovium of RA patients is an immunologic response to a fibroblast-associated antigen in the synovial membrane.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243465     DOI: 10.1002/art.1780230103

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  3 in total

Review 1.  Etiology of rheumatoid arthritis.

Authors:  T Kouri
Journal:  Experientia       Date:  1985-04-15

2.  Antibodies to cultured rat heart cells in sera of patients with rheumatoid arthritis.

Authors:  R More; Z Stern; Y Galon; A Laufer
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

3.  Plasma membrane glycoproteins of cultured rheumatoid synovial fibroblasts.

Authors:  T Kouri; E Vuorio
Journal:  Clin Rheumatol       Date:  1983-06       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.